Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

New Better Care, Better Value Indicators

The NHS Institute for Innovation and Improvement has released two new Better Care, Better Value indicators and revised the existing low cost statin indicator.

The existing indicator details the proportion of statin prescribing that consisted of low cost statins, namely simvastatin and pravastatin. This has been revised to now include ezetimibe in the denominator. The reports can be accessed online.

The two new indicators analyse low cost prescribing for drugs affecting the renin-angiotensin system and low cost proton pump inhibitors. The former measures the number of prescriptions written for angiotensin converting enzyme (ACE) inhibitors (excluding combination products) as a proportion of all drugs affecting the renin-angiotensin system. The latter measures the number of prescriptions for low cost proton pump inhibitors (PPIs), namely omeprazole and lansoprazole but excluding Losec MUPS® and Zoton FasTabs®, as a proportion of all prescriptions for PPIs.

Action: Clinicians should already aware of the cost differences in these indicator areas and the potential for improved cost-efficiency. The introduction of these new indicators is likely to increase the focus on these areas of prescribing.

Share 'New Better Care, Better Value Indicators' on Email Share 'New Better Care, Better Value Indicators' on Delicious Share 'New Better Care, Better Value Indicators' on Digg Share 'New Better Care, Better Value Indicators' on Facebook Share 'New Better Care, Better Value Indicators' on Google+ Share 'New Better Care, Better Value Indicators' on reddit Share 'New Better Care, Better Value Indicators' on StumbleUpon Share 'New Better Care, Better Value Indicators' on Twitter

atomic-wealth

4 Comments to “New Better Care, Better Value Indicators”

  1. Maha,
    The combination product Inegy contains simvastatin. It is therefore included in the denominator for the indicator for statins. Ezetimibe as a single product is not included in the indicator at all.

    It means that the indicator is only assessing the proportion os simvastatin and pravastatin use against other statin containing products.

    Comment by Matthew Robinson — September 5, 2009 #
    Reply

  2. so what excately Does this means? I am a bit lost,
    Inegy is very expensive but still inclued as cost effective, is it excluded as cost effective?
    i need a holiday too

    Comment by Maha — September 5, 2009 #
    Reply

  3. Dave,

    Having read the document again it would seem that you are correct, ezetimibe as a single product is not included but combinations of ezetimibe with a statin (Inegy®) are included.

    Comment by Matthew Robinson — April 8, 2009 #
    Reply

  4. Re: new lipid indicator
    According to http://www.productivity.nhs.uk/definitions.aspx
    "Numerator is total number of prescription items for simvastatin and pravastatin. Denominator is total number of prescription items for all statins including combinations of exetimibe [sic] with statins. Excludes all other lipid regulating drugs."
    If this is accurate, new indicator includes Inergy but not Ezetrol on it's own .... or do I need a holiday?

    Comment by Dave Maxted — April 8, 2009 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,621 spam comments.

atomic-wealth
fond-illness
summer